Meeting
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
Authors
Patrick Heckman
University of Kentucky Healthcare, Markey Cancer Center, Lexington, KY
Patrick Heckman , Donglin Yan , Xitong Zhou , Zin Myint
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 84)
DOI
10.1200/JCO.2023.41.6_suppl.84
Abstract #
84
Poster Bd #
C11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment and survival of de novo metastatic prostate cancer in US veterans.
First Author: Martin W. Schoen
Poster
2024 ASCO Annual Meeting
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
First Author: Marc-Oliver Grimm